drugset / Trial / NCT03311724

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

NCT03311724

Phase 2 Completed 111 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.

Timeline

Start
2017-10-19
Primary completion
2018-04-24
Completion
2018-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 12 mg Subcutaneous
Subject Tirzepatide Peptide 15 mg Subcutaneous